Rebecca L Achey1, Haley Gittleman2,3, Julia Schroer2, Vishesh Khanna4, Carol Kruchko1,3, Jill S Barnholtz-Sloan2,3. 1. Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio. 2. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio. 3. Central Brain Tumor Registry of the United States, Hinsdale, Illinois. 4. Department of Internal Medicine, Stanford University, Stanford, California.
Abstract
BACKGROUND: Meningioma incidence increases significantly with age. In the expanding elderly population, we lack complete understanding of population-based trends in meningioma incidence/survival. We provide an updated, comprehensive analysis of meningioma incidence and survival for individuals aged over 65. METHODS: Data were obtained from the Central Brain Tumor Registry of the United States (CBTRUS) from 2005-2015 for nonmalignant and malignant meningioma. Age-adjusted incidence rates per 100000 person-years were analyzed by age, sex, race, ethnicity, location, and treatment modalities. Survival was analyzed using Kaplan-Meier and multivariable Cox proportional hazards models for a subset of CBTRUS data. RESULTS: Nonmalignant meningioma incidence doubled from adults age 65-69 years to adults over age 85 years and was significantly greater in females than males for all ages. Malignant meningioma incidence did not differ by sex for any age grouping. Nonmalignant and malignant meningioma incidence was significantly greater in black populations versus others. Nonmalignant meningioma survival was worse with age, in black populations, and in males, including when analyzed by 5-year age groups. Surgical resection and radiation did not improve survival compared with resection alone in nonmalignant meningioma. CONCLUSIONS: This study reports increasing nonmalignant meningioma incidence in the elderly, increased incidence in black populations, and in females. In contrast, malignant meningioma incidence did not differ between sexes. Risk of death was higher for black individuals and males. Additionally, radiation did not confer a survival advantage when combined with resection for nonmalignant meningioma. Thus, we identify clinically relevant discrepancies in meningioma incidence/survival that require further study.
BACKGROUND:Meningioma incidence increases significantly with age. In the expanding elderly population, we lack complete understanding of population-based trends in meningioma incidence/survival. We provide an updated, comprehensive analysis of meningioma incidence and survival for individuals aged over 65. METHODS: Data were obtained from the Central Brain Tumor Registry of the United States (CBTRUS) from 2005-2015 for nonmalignant and malignant meningioma. Age-adjusted incidence rates per 100000 person-years were analyzed by age, sex, race, ethnicity, location, and treatment modalities. Survival was analyzed using Kaplan-Meier and multivariable Cox proportional hazards models for a subset of CBTRUS data. RESULTS:Nonmalignant meningioma incidence doubled from adults age 65-69 years to adults over age 85 years and was significantly greater in females than males for all ages. Malignant meningioma incidence did not differ by sex for any age grouping. Nonmalignant and malignant meningioma incidence was significantly greater in black populations versus others. Nonmalignant meningioma survival was worse with age, in black populations, and in males, including when analyzed by 5-year age groups. Surgical resection and radiation did not improve survival compared with resection alone in nonmalignant meningioma. CONCLUSIONS: This study reports increasing nonmalignant meningioma incidence in the elderly, increased incidence in black populations, and in females. In contrast, malignant meningioma incidence did not differ between sexes. Risk of death was higher for black individuals and males. Additionally, radiation did not confer a survival advantage when combined with resection for nonmalignant meningioma. Thus, we identify clinically relevant discrepancies in meningioma incidence/survival that require further study.
Authors: Varun R Kshettry; Quinn T Ostrom; Carol Kruchko; Ossama Al-Mefty; Gene H Barnett; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2015-05-24 Impact factor: 12.300
Authors: Vishesh Khanna; Rebecca L Achey; Quinn T Ostrom; Hunter Block-Beach; Carol Kruchko; Jill S Barnholtz-Sloan; Peter M de Blank Journal: J Neurooncol Date: 2017-08-21 Impact factor: 4.130
Authors: Ernest Barthélemy; Joshua Loewenstern; Neeraja Konuthula; Margaret Pain; Jordan Hall; Satish Govindaraj; Joshua Bederson; Raj K Shrivastava Journal: J Cancer Res Clin Oncol Date: 2018-03-02 Impact factor: 4.553
Authors: Haley R Gittleman; Quinn T Ostrom; Chaturia D Rouse; Jacqueline A Dowling; Peter M de Blank; Carol A Kruchko; J Bradley Elder; Steven S Rosenfeld; Warren R Selman; Andrew E Sloan; Jill S Barnholtz-Sloan Journal: Cancer Date: 2014-08-25 Impact factor: 6.860
Authors: Michael D Jenkinson; Mohsen Javadpour; Brian J Haylock; Bridget Young; Helen Gillard; Jacqui Vinten; Helen Bulbeck; Kumar Das; Michael Farrell; Seamus Looby; Helen Hickey; Mattheus Preusser; Conor L Mallucci; Dyfrig Hughes; Carrol Gamble; Damien C Weber Journal: Trials Date: 2015-11-14 Impact factor: 2.279
Authors: Andrew I Yang; Kobina G Mensah-Brown; Cole Rinehart; Ramie Fathy; Frederick L Hitti; Jason Brant; John Y K Lee Journal: Cureus Date: 2020-03-18
Authors: Rebecca L Achey; Sierra Vo; Gino Cioffi; Haley Gittleman; Julia Schroer; Vishesh Khanna; Robin Buerki; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neurooncol Pract Date: 2020-05-09
Authors: Sonia Bhala; Douglas R Stewart; Victoria Kennerley; Valentina I Petkov; Philip S Rosenberg; Ana F Best Journal: JNCI Cancer Spectr Date: 2021-04-08